Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Loft, Nikolai Dyrberg ; Egeberg, Alexander ; Rasmussen, Mads Kirchheiner ; Bryld, Lars Erik ; Gniadecki, Robert ; Dam, Tomas Norman ; Iversen, Lars ; Skov, Lone. / Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis : A Danish Nationwide Study. In: Acta Dermato-Venereologica. 2019 ; Vol. 99, No. 13. pp. 1224-1230.

Bibtex

@article{959d45d525ee49bdab20649ac8b9b168,
title = "Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study",
abstract = "The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman's rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on {"}Symptoms and feelings{"} made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weak-to-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life.",
author = "Loft, {Nikolai Dyrberg} and Alexander Egeberg and Rasmussen, {Mads Kirchheiner} and Bryld, {Lars Erik} and Robert Gniadecki and Dam, {Tomas Norman} and Lars Iversen and Lone Skov",
year = "2019",
month = "12",
day = "1",
doi = "10.2340/00015555-3331",
language = "English",
volume = "99",
pages = "1224--1230",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Forum for Nordic Dermato-Venereology",
number = "13",

}

RIS

TY - JOUR

T1 - Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis

T2 - A Danish Nationwide Study

AU - Loft, Nikolai Dyrberg

AU - Egeberg, Alexander

AU - Rasmussen, Mads Kirchheiner

AU - Bryld, Lars Erik

AU - Gniadecki, Robert

AU - Dam, Tomas Norman

AU - Iversen, Lars

AU - Skov, Lone

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman's rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on "Symptoms and feelings" made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weak-to-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life.

AB - The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman's rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on "Symptoms and feelings" made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weak-to-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life.

U2 - 10.2340/00015555-3331

DO - 10.2340/00015555-3331

M3 - Journal article

VL - 99

SP - 1224

EP - 1230

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 13

ER -

ID: 58983254